Cripto blocking antibodies and uses thereof
View Patent ↗The invention provides Cripto blocking antibodies, or biologically functional fragments thereof, and uses thereof. Antibodies which bind Cripto and modulate Cripto signaling are provided. Antibodies which bind Cripto and block the interaction between Cripto and ALK4 are provided. Antibodies which bind Cripto and modulate tumor growth are also provided. Antibodies which bind Cripto, modulate signaling, and modulate tumor growth are also provided. Antibodies which bind Cripto, block the interaction between Cripto and ALK4 and modulate tumor growth are provided. The invention also provides methods of using these antibodies in therapeutic, diagnostic, and research applications.
1. An isolated antibody or antigen-binding fragment thereof that specifically binds to an epitope in the domain consisting of amino acid residues 114-150 of Cripto.
2. An isolated antibody or antigen-binding fragment thereof that specifically binds to an epitope in the domain spanning amino acid residues 46-62 of Cripto.
3. The antibody or antigen-binding fragment thereof of claim 2 , wherein the Cripto comprises the amino acid sequence of SEQ ID NO: 1 or 2.
4. The antibody or antigen-binding fragment thereof of claim 1 , wherein said antibody or antigen-binding fragment thereof binds to the same epitope as an antibody produced by a hybridoma selected from the group consisting of A8G3.5 and A6F8.6.
5. The antibody or antigen-binding fragment thereof of claim 2 , wherein said antibody or antigen-binding fragment thereof binds to the same epitope as an antibody produced by a hybridoma selected from the group consisting of A10B2.18 and B3F6.17.
6. The antibody of claim 5 , which is the antibody produced by the hybridoma A10B2.18 or B3F6.17.
7. An antibody or antigen-binding fragment thereof which binds specifically to the same epitope as an antibody produced by a hybridoma selected from the group consisting of A6F8.6, A8G3.5, A10B2.18, and B3F6.17.
8. An antibody produced by a hybridoma selected from the group consisting of A6F8.6 (ATCC Accession No. PTA-3318), A8G3.5 (ATCC Accession No. PTA-3317), A8H3.1 (ATCC Accession No. PTA-3315), A10B2.18 (ATCC Accession No. PTA-3311), A27F6.1 (ATCC Accession No. PTA-3310), A40G12.8 (ATCC Accession No. PTA-3316), A17G12.1 (ATCC Accession No. PTA-3314), A1 8B3.11 (ATCC Accession No. PTA-3312), B3F6.17 (ATCC Accession No. PTA-3319), and B6G7.10 (ATCC Accession No. PTA-3313).
9. The antibody or antigen-binding fragment thereof of claim 1 , wherein said antibody or antigen-binding fragment thereof binds specifically to Cripto and is capable of blocking the interaction between Cripto and ALK4.
10. The antibody or antigen-binding fragment thereof of claim 9 , wherein said antibody or antigen binding-fragment thereof binds to the same epitope as an antibody produced by a hybridoma selected from the group consisting of A8G3.5 and A6F8.6.
11. The antibody or antigen-binding fragment thereof of claim 2 , wherein the antibody or antigen-binding fragment thereof is capable of internalizing Cripto.
12. The antibody or antigen-binding fragment thereof of claim 11 , wherein the antibody or antigen binding-fragment thereof is conjugated to a chemotherapeutic.
13. The antibody or antigen-binding fragment thereof of claim 11 , wherein the antibody or antigen-binding fragment thereof binds to an epitope to which the antibody produced by hybridoma B3F6.17 binds.
14. The antibody of claim 2 , wherein the antibody is a humanized antibody.
15. The antibody of claim 2 , wherein the antibody is a human antibody.
16. The antibody or antigen-binding fragment thereof of claim 2 , wherein the antibody or antigen-binding fragment thereof is an antibody fragment selected from the group consisting of a Fab, a Fab′, and a F(ab′)2 fragment.
17. The antibody of claim 2 , wherein the antibody is a full length antibody.
18. The antibody or antigen-binding fragment thereof of claim 2 , wherein the antibody or antigen-binding fragment thereof is a single chain antibody.
19. The antibody or antigen-binding fragment thereof of claim 2 , wherein the antibody or antigen-binding fragment thereof is conjugated to a chemotherapeutic.
20. The antibody or antigen-binding fragment thereof of claim 19 , wherein the chemotherapeutic is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.
21. The antibody or antigen-binding fragment thereof of claim 19 , wherein the chemotherapeutic is a maytansinoid.
22. The antibody of claim 2 , wherein the antibody is a humanized version of the antibody produced by the hybridoma B3F6.17.
23. An antibody which is a humanized version of the antibody produced by the hybridoma B3F6.17, wherein the antibody is conjugated to a maytansinoid.
24. A composition for administration to a subject having a tumor that expresses Cripto comprising the antibody or antigen-binding fragment thereof of claim 2 .
25. The composition according to claim 24 , further comprising a pharmaceutically acceptable excipient.
26. The composition according to claim 24 , wherein the antibody or antigen-binding fragment thereof is conjugated to a chemotherapeutic.
27. The composition according to claim 26 , wherein the chemotherapeutic is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.
28. The composition according to claim 26 , wherein the chemotherapeutic is a maytansinoid.
29. The composition according to claim 24 , further comprising a nonconjugated chemotherapeutic.